Ownership and insider activity for Autolus Therapeutics plc (AUTL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL).
Price
| Price | $1.87 |
| Market Cap | $498M |
| Exchange | NASDAQ |
| Country | GB |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Piccina Cintia | M-Exempt | 20,000 | |
| 2026-09-01 | Piccina Cintia | M-Exempt | 20,000 | $47K |
| 2026-09-02 | Piccina Cintia | S-Sale | 6,713 | $16K |
| 2026-06-29 | YOUNG WILLIAM D | A-Award | 47,500 | $76K |
| 2026-06-29 | YOUNG WILLIAM D | A-Award | 31,667 | |
| 2026-06-29 | Rao Madduri Ravin | A-Award | 47,500 | $76K |
| 2026-06-29 | Rao Madduri Ravin | A-Award | 31,667 | |
| 2026-06-29 | Richardson Ryan | A-Award | 47,500 | $76K |
| 2026-06-29 | Richardson Ryan | A-Award | 31,667 | |
| 2026-06-29 | Leiderman Elisabeth | A-Award | 47,500 | $76K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.1M | $137.1M | $189.3M | $211.4M | $154.1M | $310.3M | $382.4M | $239.6M | $227.4M | $104.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $360.6M | $196.6M |
| Receivables | $2.2M | $4.7M | $9.3M | $30.5M | $29.7M | $68000 | $29.0M | $1.0M | $48.2M | $75.8M |
| Inventory | 0 | 0 | $2.2M | 0 | 0 | 0 | 0 | 0 | $4.1M | $33.2M |
| Total Current Assets | $30.9M | $142.5M | $199.1M | $249.3M | $194.0M | $347.0M | $425.8M | $275.3M | $660.9M | $435.9M |
| Property, Plant & Equipment | $3.3M | $6.2M | $9.2M | $51.6M | $89.7M | $52.3M | $58.4M | $95.7M | $105.1M | $128.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $9.5M | 0 | $9.3M | $254000 | $158000 | $65000 | 0 | 0 | $12.4M | $19.8M |
| Total Assets | $34.2M | $148.7M | $217.7M | $303.5M | $294.2M | $405.6M | $490.3M | $375.4M | $782.7M | $589.1M |
| Accounts Payable | $1.4M | $1.9M | $3.0M | 0 | $2.3M | $431000 | $531000 | $103000 | $2.0M | $3.1M |
| Short-term Debt | 0 | 0 | 0 | $2.5M | $3.6M | 0 | 0 | 0 | 0 | $14.6M |
| Total Current Liabilities | $2.7M | $5.0M | $12.5M | $25.0M | $33.6M | $28.6M | $46.4M | $44.7M | $60.7M | $73.4M |
| Long-term Debt | 0 | 0 | $221000 | 0 | 0 | $47.0M | 0 | 0 | 0 | $270.2M |
| Total Liabilities | $3.5M | $6.1M | $12.5M | $48.7M | $84.2M | $92.2M | $191.6M | $263.9M | $355.4M | $410.9M |
| Retained Earnings | -$28.2M | -$47.9M | $163.8M | -$237.2M | -$379.2M | -$521.3M | -$670.2M | -$878.6M | -$1.10B | -$1.39B |
| Total Equity | $30.7M | $142.6M | $205.1M | $254.8M | $210.0M | $313.3M | $298.7M | $111.5M | $427.3M | $178.1M |
| Total Debt | $188000 | $265000 | $221000 | $26.2M | $54.2M | $68.0M | $24.3M | $53.0M | $52.6M | $351.6M |
| Net Debt | -$27.9M | -$136.8M | -$189.1M | -$185.2M | -$99.9M | -$242.3M | -$358.2M | -$186.6M | -$535.4M | $50.9M |
| Working Capital | $28.2M | $137.4M | $186.6M | $224.3M | $160.3M | $318.4M | $379.4M | $230.6M | $600.2M | $362.5M |
Financial Health
| Debt / Equity | 1.12 |
| Current Ratio | 4.89 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -3.23 |
Profitability
| Return on Equity | -178.58% |
| Return on Invested Capital | -57.49% |
| Return on Assets | -56.77% |
| Gross Margin | 15.66% |
| Operating Margin | -210.76% |
| Net Margin | -238.62% |
Related companies: ADCT · ANNX · AURA · BNTC · LBRX · NMRA · QSI
Explore sector: Healthcare · Biotechnology
More sections of AUTL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks